We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Snaptrip is a marketplace for last minute, discounted UK cottage, lodge and apartment holidays.
days to go: Expired investment: £1,477,852
Investly are an invoice financing marketplace that help European businesses finance their invoices by bringing them the best price from multiple providers. In 2 years they have financed just over £18m worth of invoices.
days to go: Expired investment: £679,085
Brickowner aims to become the leading service provider for property developers and asset managers, ensuring benefits for both parties. The company undertakes background checks of investors on its portal for the benefit of asset managers. It also ensures that investors can easily navigate its portal and find deals that suit their financial appetite. Brickowner successfully exited five investment rounds despite two investments happening in the wake of COVID-19. The platform has over 3,000 investors registered with over 700 active investors. It has overseen £14 million worth of investment on its portal to date. Brickowner will use the investment towards technology up-gradation, hire strategic personnel to expand marketing, and increase its marketing spend.

Pitch Rated

56%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £132,528
CrowdProperty is a specialist property project lending platform that matches quality property professionals undertaking quality property projects with institutional/private investors of capital for value-creating property projects. It seeks to ensure profits for borrowers, lenders, the under-supplied UK housing environment, and the UK economy through its business model. The company claims to have recently closed a £300 million funding line from a global asset manager. It has lent upwards of £140 million with £180 million+ originated facilities, gained recognition by Deloitte Fast50 and FT1000 as a 'High Growth Business', and built a proprietary and scalable technology platform. CrowdProperty has also launched CrowdProperty Australia, leveraging its asset-class expertise, scalable proprietary technology and IP from the UK business in the Australian market. The company states it will use the investment to grow its property team, evolve its technology platform further, acquire more customers, and grow its business.
days to go: Expired investment: £1,815,319
Desuto have developed a support platform that is designed to help simplify professionals work. Desuto's ehealthtracker helps users to choose the best option when making tough decisions about care.   
days to go: Expired investment: £55,677
Warehouse home cater to urban living by specialising in the industrial home styling niche. They publish high end print and digital magazines bi-annually which feature styling tips and also real homes, and also have an online shop with carefully sourced designs for the ever growing industrial style home. 
days to go: Expired investment: £42,330
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph